Literature DB >> 14667132

Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.

L S Stilgren1, L M Hegedüs, H Beck-Nielsen, B Abrahamsen.   

Abstract

The effect of parathyroid hormone (PTH) on the production of osteoprotegerin (OPG) remains controversial. Most in vitro studies indicate that PTH decreases OPG secretion by the osteoblast, but in vivo observations are conflicting. In primary hyperparathyroidism (PHPT), hypersecretion of PTH leads to enhanced bone resorption and formation with increased risk of fracture. Patients with PHPT are cured by surgery, resulting in normalization of PTH levels and bone metabolism, but the concomitant effects on OPG production are not known. The hypothesis of the present study was that the circulating level of OPG is diminished in patients with PHPT and increases with successful parathyroidectomy. We also speculated that serum OPG may determine the magnitude of bone loss up to the time of surgery. In the present study, 20 patients (17 women and 3 men, mean age 62 y) with PHPT who were candidates for surgical cure were examined before and 12 months after surgery. Bone turnover markers decreased and BMD increased significantly after surgery. Serum OPG did not correlate with PTH before surgery (r = 0.07, P = 0.77) and was not affected by parathyroidectomy (P = 0.79). After normalization of PTH, bone formation markers showed significant (P1NP) and near-significant (osteocalcin) correlations with serum OPG. In conclusion, serum OPG is not decreased in patients with PHPT, nor is serum OPG to any demonstrable extent regulated by PTH pre- or postoperatively.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667132     DOI: 10.1007/s00223-002-2100-8

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  7 in total

Review 1.  Bone turnover in hyperparathyroidism.

Authors:  Katharina Kerschan-Schindl
Journal:  Wien Med Wochenschr       Date:  2012-07-18

2.  Effect of parathyroidectomy on osteopontin and undercarboxylated osteocalcin in patients with primary hyperparathyroidism.

Authors:  Raelene E Maser; M James Lenhard; Ryan T Pohlig; P Babu Balagopal; Raafat Abdel-Misih
Journal:  Endocr Res       Date:  2017-09-22       Impact factor: 1.720

Review 3.  Bone turnover markers in primary hyperparathyroidism.

Authors:  Aline G Costa; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

4.  Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease.

Authors:  Y Y Yuan; P J Kostenuik; M S Ominsky; S Morony; S Adamu; D T Simionescu; D M Basalyga; F J Asuncion; T A Bateman
Journal:  Osteoporos Int       Date:  2007-11-24       Impact factor: 4.507

5.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

6.  "Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density".

Authors:  María Piedra; María T García-Unzueta; Ana Berja; Blanca Paule; Bernardo A Lavín; Carmen Valero; José A Riancho; José A Amado
Journal:  BMC Med Genet       Date:  2011-12-20       Impact factor: 2.103

7.  Serum bone resorption markers after parathyroidectomy for renal hyperparathyroidism: correlation analyses for the cross-linked N-telopeptide of collagen I and tartrate-resistant acid phosphatase.

Authors:  Kuo-Chin Hung; Chung-Yu Huang; Chuan-Chieh Liu; Chih-Jen Wu; Shao-Yuan Chen; Pauling Chu; Chia-Chao Wu; Lan Lo; Liang-Kuang Diang; Kuo-Cheng Lu
Journal:  ScientificWorldJournal       Date:  2012-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.